CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 190 enrolled
Drug / intervention
EBV +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01796392
NCT01796392N/ACompleted
CompareCT.gov

Lung Function Improvement After Bronchoscopic Lung Volume Reduction With Pulmonx Endobronchial Valves Used in Treatment of Emphysema

Pulmonx Corporation·interventional·Posted Feb 21, 2013·Updated Jun 15, 2023

In Brief

A clinical study evaluating EBV and Optimal Medical Management for Emphysema. Completed, enrolled 190 participants across 23 sites in 4 countries.

Detailed Summary

The purpose of this research is to study an investigational medical device that is designed to produce lung volume reduction in diseased areas of the lungs in patients with severe emphysema.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEmphysema
CountriesBrazil, Netherlands, United Kingdom, United States
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 21, 2013
Enrollment StartJul 1, 2013
Primary CompletionSep 1, 2017
Study CompletionApr 1, 2023
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 13.4 years ago

Interventions

EBVdevice

This study arm will undergo EBV treatment and also receive optimal medical management, including smoking cessation program support, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.

Optimal Medical Managementother

This study arm will receive optimal medical management, including smoking cessation program support, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.